# üìä Research Reports Index
**Generated:** February 11, 2026, 9:37 PM PST

---

## All Reports

| # | Report | Key Findings |
|---|--------|--------------|
| 01 | [Competitor Landscape](01-COMPETITOR-LANDSCAPE.md) | DermaSensor is main threat (FDA cleared), liquid biopsy = adjacent market, HelioFlux has unique non-invasive + pre-lesion angle |
| 02 | [Grant Opportunities](02-GRANT-OPPORTUNITIES.md) | ‚ö†Ô∏è SBIR/STTR EXPIRED (Oct 2025) ‚Äî Focus on Mark Foundation, Prevent Cancer Foundation, ACS, AACR, V Foundation |
| 03 | [AI Training Jobs](03-AI-TRAINING-JOBS.md) | Anthropic = best target (no PhD required), Outlier = quick income, $15-50/hr contract to $120K+ full-time |
| 04 | [Media & Press Targets](04-MEDIA-PRESS-TARGETS.md) | Tier 1: Rebecca Robbins (NYT), John Carroll (Endpoints), Frank Vinluan (MedCity) |
| 05 | [Patent Landscape](05-PATENT-LANDSCAPE.md) | UPE clinical devices = less crowded, sign Mike's engagement ($2,500), file full patent within 12 months |
| 06 | [Strategic Partners](06-STRATEGIC-PARTNERS.md) | Forefront Dermatology (largest chain), Moffitt Cancer Center (Business of Biotech), Hamamatsu (existing) |
| 07 | [Biotech Investors](07-BIOTECH-INVESTORS.md) | Aglaia Oncology (perfect fit), IndieBio ($500K + lab), Codon Capital, Boehringer Venture |
| 08 | [AI Daily Brief Curriculum](08-AI-DAILY-BRIEF-CURRICULUM.md) | Kelly is AHEAD on 5/6 weeks ‚Äî already at Week 7-10 level (building AI apps) |

---

## Quick Stats

**Total research compiled:** 8 reports, ~40KB of strategic intelligence

**Time saved:** Dozens of hours of individual research

---

## Top 5 Immediate Actions

1. **Sign Mike's patent engagement** ‚Äî $2,500 retainer (blocking item)
2. **Apply to Aglaia Oncology** ‚Äî Perfect mission alignment
3. **Sign up for Outlier.ai** ‚Äî Immediate income as science specialist
4. **Apply to Anthropic** ‚Äî Best full-time AI job target
5. **Research Forefront Dermatology leadership** ‚Äî Largest partnership target

---

## Surprising Findings

üö® **SBIR/STTR is dead** ‚Äî Programs expired Oct 2025, Congress hasn't reauthorized

üí° **DermaSensor cleared in Jan 2024** ‚Äî FDA-cleared competitor exists, BUT requires visible lesion (HelioFlux advantage: earlier)

üìà **Biophotonics market: $62.6B** ‚Äî Large and growing market

üéØ **Aglaia Oncology exists** ‚Äî VC fund that ONLY invests in oncology early detection

---

## Report Locations

All reports in: `/home/kellybot/.openclaw/workspace/research-reports/`

---

*Generated by Kip ü¶â for Kelly*
